Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic …
G Ntaios, V Papavasileiou, K Makaritsis, K Vemmos… - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …
coming from randomized controlled trials. We aimed to summarize all available evidence …
Adherence to oral anticoagulant therapy in patients with atrial fibrillation
Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
Effectiveness and safety of non–vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses
Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
A Zirlik, C Bode - Journal of thrombosis and thrombolysis, 2017 - Springer
Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more
than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial …
than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial …
Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis
Y Bai, H Deng, A Shantsila, GYH Lip - Stroke, 2017 - Am Heart Assoc
Background and Purpose—This study was designed to evaluate the effectiveness and
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients
S Deitelzweig, X Luo, K Gupta, J Trocio… - … medical research and …, 2017 - Taylor & Francis
Objective: To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB)
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …
Risk of gastrointestinal bleeding during anticoagulant treatment
A Lanas-Gimeno, A Lanas - Expert opinion on drug safety, 2017 - Taylor & Francis
Introduction: Gastrointestinal bleeding (GIB) is a major problem in patients on oral
anticoagulation therapy. This issue has become even more pressing since the introduction …
anticoagulation therapy. This issue has become even more pressing since the introduction …
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban …
A Amin, A Keshishian, J Trocio, O Dina… - … medical research and …, 2017 - Taylor & Francis
Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …